Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF vs TDF for Preventing HBV MTCT in Pregnant Women
NCT06947356Phase 3Recruiting
- Sponsor
- Guangzhou Eighth People's Hospital
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenofovir alafenamide in hepatitis B (HBV) (2 arms), sponsored by Guangzhou Eighth People's Hospital. Primary endpoint: Mother-to-child transmission rate of HBV at 28 weeks. Started May 2025; status: recruiting.
02
Drugs
tenofovir alafenamide
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT06947356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947356.